Rising CEA Levels in Lung Adenocarcinoma Treatment - Pulmonology

More Info

---

The rise in CEA (Carcinoembryonic Antigen) levels in patients with lung adenocarcinoma can be concerning and warrants careful evaluation. In your case, the increase from 1.2 to 2.26 within a short period could suggest several possibilities, but it does not definitively indicate disease progression or resistance to treatment on its own.

CEA is a tumor marker that is often elevated in various malignancies, including lung cancer, and can be used to monitor treatment response or disease progression. However, it is important to note that CEA levels can fluctuate for various reasons, including smoking, inflammation, and other benign conditions. Therefore, an isolated increase in CEA should not be interpreted as a definitive sign of cancer progression or resistance to therapy without correlating clinical and imaging findings.

In your situation, it is essential to consider the following points:
1. Monitoring and Imaging: The best way to assess whether the cancer is progressing or if there is resistance to the current treatment is through imaging studies, such as CT scans or PET scans. These imaging modalities can help identify any new lesions or growth of existing tumors. If imaging shows no significant changes, it may suggest that the increase in CEA is not indicative of disease progression.

2. Potential Resistance: If imaging does reveal new or enlarged lesions, it could suggest that the cancer is becoming resistant to the current targeted therapy (in your case, Anlotinib). Resistance can occur due to various mechanisms, including mutations in the tumor that render the targeted therapy less effective. If resistance is suspected, your oncologist may consider switching to a different treatment strategy.

3. Next Steps in Treatment: If resistance to Anlotinib is confirmed, the next steps in treatment could involve several options. These may include switching to a different targeted therapy, potentially a third-generation EGFR inhibitor if you have an EGFR mutation, or considering chemotherapy. The choice of treatment will depend on various factors, including the specific characteristics of your cancer, previous treatments, and overall health.

4. Consultation with Oncologist: It is crucial to have an open discussion with your oncologist regarding the rising CEA levels and any imaging results. They can provide personalized recommendations based on the most current information about your cancer and its behavior.

In summary, while rising CEA levels can be concerning, they should be interpreted in the context of imaging studies and clinical findings. It is essential to maintain close communication with your healthcare team to determine the best course of action moving forward. Regular monitoring and timely adjustments to your treatment plan are key in managing lung adenocarcinoma effectively.